Sutura Therapeutics Ltd

Optimised Enzyme Delivery to Lysosomes with Sutura’s Stapled Peptides   Pompe disease is a severe genetic disorder caused by the build-up of glycogen in the body's cells, leading to progressive muscle weakness and respiratory problems. The latest enzyme replacement therapies have significantly enhanced cell entry, but only become active once they reach the lysosome and in a truncated form, which breaks down glycogen.   Our stabilised peptide conjugates are also highly proficient at entering the cell but seem to have a severalfold greater affinity for the lysosome. Furthermore, we have shown that our stabilised peptide conjugates are naturally processed into the active 76 and 70kda forms of the enzyme. Together, these confer a higher glycogen-clearing activity than the current standard of care.   Stay tuned for more insights into how our innovative solutions are making a difference in the lives of Pompe disease patients.   #PompeDisease #RareDiseases #HealthcareInnovation #SuturaTherapeutics #FightRareDiseases

Unlocking New Potential in Therapeutic Development with CPPs At Sutura Therapeutics, we are interested in developments accross the cell-penetrating peptides (CPP) space. One that caught our eye was a study published in Nucleic Acids Research which highlights a significant advancement that uses CPPs to deliver a peptide payload to a DNA target, with potent anti-cancer effect. Our CPPs have also shown the ability to target payloads to the nucleus (for applications in rare disease) so we are especially excited to see others harnessing these class effects to enhance the viability and effectiveness of early-stage therapeutics in cancer.   Study Highlights: • Title: Unlocking the potential of protein-derived peptides to target G-quadruplex DNA: from recognition to anticancer activity • Authors: Francesco Merlino, Simona Marzano, Pasquale Zizza, et al. Summary: The study describes how certain peptides have significant promise as potent and selective binders of the G-quadruplex DNA structures. However, the authors observed that the most promising of these peptides does not exhibit cancer cell cytotoxicity, because of an inability to penetrate the cell membrane. The authors solved the problem by conjugating their payload to a cell penetrating peptide which chaperoned their molecule into the cell. The authors observed that these conjugates had “remarkable efficacy in facilitating cell entry and thereby enhancing the biological activity of [their compound]”  This breakthrough illustrates how CPPs can transform early-stage therapeutics that might otherwise show limited potential. Read the full article to see how CPPs are paving the way for new therapeutic strategies: https://lnkd.in/dUttV8U6 #Biotechnology #CPP #Therapeutics #SuturaTherapeutics #HealthcareInnovation #DrugDelivery

Sutura’s Stapled Peptides: Transforming the Treatment of Pompe Disease   Pompe disease is a severe genetic disorder in which the build-up of glycogen in the body's cells leads to progressive muscle weakness and respiratory problems. The harsh environment enroute to the muscle, and poor cellular uptake once there, means that very little enzyme replacement therapy (ERT) ever reaches the target site. Patients must be given frequent high doses with annual treatment costs of up to $630,000/year. Our innovative approach is a game-changer in the management of Pompe disease. ERT conjugated to stapled peptides retains activity and enjoys improved requisition into the cell. This profile promises lower doses and fewer complications, potentially allowing patients to be treated for longer, with better outcomes.    Follow us for more updates on our groundbreaking research and advancements in Pompe disease therapy.   #PompeDisease #RareDiseases #HealthcareInnovation #FightRareDiseases 

🧪 Meet Mavra Farooq: Scientist CMC at Sutura Therapeutics We are excited to introduce Mavra Farooq, a key member of our Chemistry, Manufacturing, and Controls (CMC) team at Sutura Therapeutics. With five years of experience in peptide manufacturing, Mavra specialises in Solid-Phase Peptide Synthesis (SPPS) and plays a crucial role in synthesising peptides for the development and optimisation of our drug conjugate platform. Mavra's expertise in SPPS and her experience in synthesising peptides for research, clinical development, and commercial applications make her an invaluable asset to our team. Her dedication to advancing the development of innovative medicinal products aligns perfectly with Sutura's mission to enhance current cellular delivery methods and positively impact the lives of patients with rare diseases and their families. We are thrilled to have Mavra on board as we continue to push the boundaries of drug conjugate technology and develop transformative therapies for those in need. #DrugConjugates #PeptideSynthesis #WomeninSTEM

🔬 Enhanced Enzyme Delivery for Pompe Disease Pompe disease is a severe genetic disorder caused by the buildup of glycogen in the body's cells, leading to progressive muscle weakness and respiratory problems. Even if treated with the current standard treatment, enzyme replacement therapy (ERT), those with infant-onset Pompe rarely survive beyond adolescence.   At Sutura Therapeutics, we're pioneering improved treatments for Pompe disease using our innovative stapled peptides. By conjugating the therapeutic enzyme to these peptides we have been able to significantly enhance its effectiveness and delivery to the muscle cells.   A fluorescent reporter protein vividly demonstrates this advancement, showcasing how our peptides can achieve greater cellular uptake.   Stay connected with us to learn more about how our solutions are transforming the landscape of Pompe disease treatment.   #PompeDisease #RareDiseases #HealthcareInnovation

Intracellular delivery remains a key challenge for antiviral therapies, as noted in an insightful paper published in the May 2024 issue of the Cellular Signalling research journal (volume 117): "Instead of putting efforts toward finding new antiviral therapy drugs, it is suggested that the delivery system be optimized. Developing an effective and safe intracellular delivery vehicle (such as CPPs) is crucial for increasing the efficiency of antiviral medications in vivo." At Sutura Therapeutics, we couldn't agree more! We have developed a new class of stabilised CPPs which have demonstrated enhanced delivery of a variety of macromolecular payloads, with the potential to transform existing therapies, salvage promising failures, or develop novel new gene and protein-targeting treatments. Read the full article for a comprehensive look at CPP uptake pathways and their implications for drug delivery, gene therapy, and vaccine development: https://lnkd.in/g9pgXDqH #CellPenetratingPeptides #AntiviralTherapy #DrugDeliveryOptimisation #IntracellularDelivery

Did you know? Pompe disease is a severe genetic disorder. Even if treated, those with infant-onset Pompe rarely survive beyond early childhood. The current standard treatment, enzyme replacement therapy (ERT), can extend life expectancy into adolescence. However, ERT has significant shortcomings. It does not target skeletal muscle effectively, leading to progressive muscle weakness and respiratory issues over time. Moreover, ERT requires lifelong bi-weekly infusions, which can be burdensome for patients and families.   There is an urgent unmet need for more efficient therapies that can provide better disease management, improve quality of life, and extend survival. At Sutura Therapeutics, we're committed to addressing this unmet need by developing targeted treatments that significantly improve outcomes for patients with this severe disease.   Follow us to learn more about our efforts and the latest developments in Pompe disease research.   #PompeDisease #RareDiseases #HealthcareInnovation #FightRareDiseases

A fascinating overview by Biorbyt on the immense therapeutic potential of cell penetrating peptides (CPPs) for delivering therapeutic drugs, including proteins and nucleic acids into cells - with applications spanning cancer, neurodegenerative and genetic disorders. As the article points out, persistent challenges exist around CPP stability, payload delivery efficiency and toxicity. At Sutura Therapeutics Ltd, our patented drug conjugate platform featuring stapled peptides is laser-focused on overcoming these exact limitations.   By stitching and stapling CPPs to enhance their stability, cell penetration and target interaction, we aim to significantly boost the stability of CPP-based delivery of enzymes, proteins and oligonucleotides. This opens up new opportunities across a variety of rare diseases with high unmet need.   The promise of next-generation CPPs is immense and we're excited to be pushing innovation in this field. Read the article to learn more about CPPs and stay tuned for updates on how Sutura is working to translate their potential into reality.   #CellPenetratingPeptides #CPPs #DrugDeliveryOptimisation #IntracellularDelivery

🎂🧬 Sweet Science! We're delighted to showcase another wonderful creation from the talented Sajida at Wee Buns. This time, a birthday cake for one of our team members featuring a design that incorporates DNA sequencing and molecules! Thank you, Sajida, for another incredible and very delicious creation that has been powering our science team! Here’s to more scientific discoveries and team celebrations! 🌟🍰 https://bit.ly/wee-buns #SuturaTherapeutics #ScienceCake #BiotechBakes

A Successful BioTrinity 2024 for Sutura! 🙌 We are delighted to report that our CEO, Dr. Edwin Wagena, had a great experience presenting at the BioTrinity 2024 conference last week. The event, organised by OBN (UK) Ltd, brought together leading minds in the life sciences sector to discuss the latest advancements and future collaborations. Dr. Wagena's presentation during the Rare Diseases R&D Spotlight on Tuesday 23rd April explored Sutura's recent breakthroughs and their potential to revolutionise healthcare and treatment methodologies. We want to extend our gratitude to the organisers at OBN (UK) Ltd for putting together such a valuable event and for giving us the opportunity to share our work with the community. The connections made and the insights gained will undoubtedly shape our future endeavours. As always, we remain committed to pushing the boundaries of biotechnology and welcome further discussions with potential partners. Feel free to reach out to us at LetsTalk@Sutura.com to explore how we can collaborate to create a healthier future. #BioTrinity2024 #SuturaTherapeutics #DrugConjugates #Biotechnology